Physician profile
Lawrence Reccoppa
NPI 1215095534
$968,069.41
in general payments reported to CMS, 2019-2025
14 companies · $339K in 2025
The $339K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126K · 2020: $37K · 2021: $89K · 2022: $99K · 2023: $90K · 2024: $187K · 2025: $339K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $476K · Travel and Lodging: $88K · Consulting Fee: $32K · Food and Beverage: $21K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $476,083.00 |
| Travel and Lodging | $87,538.59 |
| Consulting Fee | $32,359.28 |
| Food and Beverage | $21,158.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $385,812.76 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $209,709.85 | 2024-2025 | Fanapt |
| Alkermes, INC. | $135,232.21 | 2019-2024 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $122,746.39 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $68,675.99 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25,636.53 | 2019-2025 | Abilify Asimtufii |
| Abbvie INC. | $10,629.68 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $8,411.41 | 2021-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $537.76 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $359.33 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $160.09 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $96.56 | 2019-2024 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $45.58 | 2024 | Auvelity |
| Allergan, INC. | $15.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Reccoppa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.